Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
Status:
Active, not recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial
ovarian cancer is able to improve the median Overall Survival (OS) by 12 months. In that
hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion
and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10%
failure, an overall number of 444 patients is required.